Genmab — November 2018
-
Jeg tror faktisk, der er noget om det med at Dara skuffede i solide, der har trykket evalueringen. Uanset at der officielt ikke var indregnet noget fra solide, så var retorikken fra JvdW så optimistisk, at det føltes som en skuffelse langt over det, der var berettiget.
-
jep - det hjælper gevaldigt på tonen, når skribenter afholder sig fra at kalde andre nedsættende ting
-
Troede det kom frem lige efter sidste dato for tilmelding?? Jeg venter til 20 November
-
Om alt går vel så har har vi ofa i MS ob TV på markedet i 2020. Dara i Amy og teprotumumab i 2021. 4 nye medikamenter! Oh så taler man om en dårlig pibe! Det er da sk... godt Egon. Whats not to like JV?
-
så er der allerede 10 kroner ekstra i "ofa-kassen"
-
EL sometime ago estimated that teprotumumab could yield about 50M USD in royalties yearly. That is not bad for a product we hardly mention here...
-
i doubt you understand the meaning of estimate....;-)
-
Teprotumumab Phase 3 top line results Q2 19 https://www.businesswire.com/news/home/20180904005271/en/Horizon-Pharma-plc-Completes-Enrollment-Confirmatory-Phase
-
Vores ven fra i forgårs har ændret sit tweet. Så der er stadig håb om MRD>50% https://twitter.com/NBahlis/status/1057795612530237440
Hello! It looks like you're interested in this conversation, but you don't have an account yet.
Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.
With your input, this post could be even better 💗
Tilmeld Log ind